The new facility will be operating in accordance with current Good Manufacturing Practices (GMP)
Novo Nordisk opens a new manufacturing facility in Russia for formulation and filling of modern insulin for the treatment of diabetes. The production will cover both Penfill cartridges and FlexPen prefilled insulin injection pens for the Russian market.
The new facility will be operating in accordance with current Good Manufacturing Practices (GMP), and is located in Technopark Grabtsevo in the Kaluga region of Russia.
"The manufacturing facility in Kaluga is a sign of our long-term commitment to people with diabetes in Russia, where close to 10 million people have the disease according to local studies. With our investment in local manufacturing, we ensure availability of high-quality modern insulins to the people with diabetes in Russia who rely on our products every day," said Mr Lars Rebien Sørensen, CEO of Novo Nordisk.
Novo Nordisk also has production sites in Denmark, Brazil, China, France and the US.
